NCT00049543View on ClinicalTrials.gov

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

503

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Adenocarcinoma of the LungAdenosquamous Cell Lung CancerBronchoalveolar Cell Lung CancerLarge Cell Lung CancerSquamous Cell Lung CancerStage IB Non-small Cell Lung CancerStage IIA Non-small Cell Lung CancerStage IIB Non-small Cell Lung CancerStage IIIA Non-small Cell Lung Cancer
Interventions
DRUG

gefitinib

Given PO

OTHER

placebo

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

K7L 3N6

National Cancer Institute of Canada Clinical Trials Group, Kingston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00049543 - Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery | Biotech Hunter | Biotech Hunter